Clinical Trial Update: Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing canagliflozin (Invokana) to standard dual therapy for type 2 diabetes during Ramadan has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• INVOKANA (CANAGLIFLOZIN)

Snippet

Sponsor: University of Leicester | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED